Alexandre Malek

Dr. Alexandre Malek

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2022 in Infection
Verified
Journal Article
Closed access
PDF file
DRDinesh Regalla
Dinesh Regalla
MVMollie VanNatta
Mollie VanNatta
MAMohammad Alam
Mohammad Alam
AMAlexandre Malek
Alexandre Malek

12 April 2020 in Expert Review of Anti-infective Therapy
Verified
Journal Article
Closed access
AMAlexandre Malek
Alexandre Malek
IRIssam I. Raad
Issam I. Raad
Introduction: Central line–associated bloodstream infections (CLABSI) are a frequent cause of healthcare-associated infections, increasing healthcare costs and decreasing the quality of life for critically and chronic ill patients such as those with cancer. These infections are largely preventable and have been significantly reduced throughout the United States. However, further reduction of CLABSI requires continued innovation in preventive strategies. Areas covered: We provide an overview of the recent medical literature on catheter-related infections among cancer patients, discussing epidemiology, risk factors, and pathogenesis of CLABSI with a focus on the newest and current preventive measures. The data discussed here were retrieved mainly from clinical trials, meta-analyses, and systematic reviews published in the English language using a MEDLINE database search from January 01, 1990 until end of December 2019. Expert opinion: The growing impact of CLABSI on the healthcare setting and mortality and morbidity rates in cancer patients calls for novel technologies for preventing central line–related infections. Advances in antimicrobial lock therapy are not limited to salvage therapy but have also provided a novel and promising prophylactic approach to CLABSI. Also, the use of antimicrobial-coated catheters with chlorhexidine-impregnated dressings, along with the application of insertion and maintenance bundles, are an effective and cost-effective approach for preventing central line–related infections.

22 March 2021 in Pathogens
Verified
Journal Article
Open access
PDF file
AKAhmed Omar Kaseb
Ahmed Omar Kaseb
YMYehia I. Mohamed
Yehia I. Mohamed
AMAlexandre Malek
Alexandre Malek
Issam I RaadIssam I Raad
Issam I Raad
LALina Altameemi
Lina Altameemi
QMQing Ma
Qing Ma
The novel coronavirus disease 2019 (COVID-19) pandemic has led to an unprecedented threat to the international community and raised major concerns in terms of public health safety. Although our current understanding of the complexity of COVID-19 pathogenesis remains limited, the infection is largely mediated by the interaction of viral spike protein and angiotensin-converting enzyme 2 (ACE2). The functional importance of ACE2 in different demographic and comorbid conditions may explain the significant variation in incidence and mortality of COVID-19 in vulnerable groups, and highlights its candidacy as a potential therapeutic target. We provide evidence supporting the idea that differences in incidence and severity of COVID-19 infection may be related to ACE2. Emerging data based on the prevalence and severity of COVID-19 among those with established high levels of ACE2 expression strongly support our hypothesis. Considering the burden of COVID-19 infection in these vulnerable groups and the impact of the potential therapeutic and preventive measures that would result from adopting ACE2-driven anti-viral strategies, our hypothesis may expedite global efforts to control the current COVID-19 pandemic.

1 November 2021 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
PCPatrick Chaftari
Patrick Chaftari
ACAnne-Marie P. Chaftari
Anne-Marie P. Chaftari
RHRay. Y. Hachem
Ray. Y. Hachem
Sai-Ching Jim YeungSai-Ching Jim Yeung
Sai-Ching Jim Yeung
HDHiba Dagher
Hiba Dagher
IRIssam Raad
Issam Raad
Background: The Multinational Association for Supportive Care in Cancer (MASCC) risk index has been utilized to determine the risk for poor clinical outcomes in patients with febrile neutropenia (FN) in an emergency center (EC). However, this index comprises subjective elements and elaborated metrics limiting its use in ECs. We sought to determine whether procalcitonin (PCT) level (biomarker of bacterial infection) with or without lactate level (marker of inadequate tissue perfusion) offers a potential alternative to MASSC score in predicting the outcomes of patients with FN presenting to an EC.Methods: We retrospectively identified 550 cancer patients with FN who presented to our EC between April 2018, and April 2019, and had serum PCT and lactate levels measured.Results: Compared with patients with PCT levels 2.2 mmol/L were more likely to be admitted and have an LOS >7 days, BSI, and 14‐day mortality than patients with lower levels. PCT level was a significantly better predictor of BSI than MASSC score (p = 0.003) or lactate level (p < 0.0001).Conclusions: Procalcitonin level is superior to MASCC index in predicting BSI. The combination of PCT and lactate levels is a good predictor of BSI, hospital admission, and 14‐day mortality and could be useful in identifying high‐risk FN patients who require hospital admission.

30 September 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
MVMollie VanNatta
Mollie VanNatta
LGLaurie Grier
Laurie Grier
MKMuhammad H Khan
Muhammad H Khan
PCPaulette Pinargote Cornejo
Paulette Pinargote Cornejo
MAMohammad Alam
Mohammad Alam
AMAlexandre Malek
Alexandre Malek
The treatment of patients with infection secondary to carbapenem-resistant Acinetobacter baumannii with emerging cefiderocol resistance remains challenging and unclear. We present a case of in vivo emergence of pandrug-resistant A baumannii that was successfully treated with the compassionate use of investigational sulbactam-durlobactam–based antibiotic regimen. We also performed a longitudinal genomic analysis of the bacterial isolates and showed the development of resistance and genetic mutations over time.

21 June 2020 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
AMAlexandre Malek
Alexandre Malek
MKMelissa Khalil
Melissa Khalil
RHRay Hachem
Ray Hachem
ACAnne Marie Chaftari
Anne Marie Chaftari
JFJohny Fares
Johny Fares
IRIssam I Raad
Issam I Raad
Checkpoint inhibitor (CPI) immunotherapy has revolutionized cancer treatment. However, immune-related adverse events and the risk of infections are not well studied. To assess the infectious risk of CPIs, we evaluated the incidence of infections in lung cancer patients treated with CPIs plus conventional chemotherapy (CC) vs CC alone. We performed a retrospective comparative study of patients with advanced non–small cell lung cancer who received CPIs combined with CC and those treated with CC alone at our institution during January 2016 to February 2019. We compared clinical characteristics, treatments, and outcomes including infection rate and mortality between the groups. We identified 123 patients for the CPI group and 147 patients for the control (CC) group. Eighteen patients (15%) in the CPI group and 33 patients (22%) in the control group developed infections (P = .1). Pneumonia was the most common infection encountered in both groups. Urinary tract infection was higher in the CC group (40%) than in the CPI group (9%) (P = .01). On multivariable analysis, chronic obstructive pulmonary disease (P = .024), prior use of corticosteroids (P = .021), and neutropenia (P < .001) were independent risk factors for infection and severe infection requiring hospital admission. Chronic kidney disease (P = .02), prior cancer treatment (P = .023), and neutropenia (P < .0001) were identified as independent risk factors for all-cause mortality. Lung cancer patients treated with CPIs combined with CC have a comparable risk of infection to those treated with CC alone, although there is a trend towards fewer infections in those given CPIs, particularly when it comes to urinary tract infections.